查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1858267

扩大性心肌病治疗市场依治疗分类、治疗方法、给药途径、最终用户和分销管道划分－2025-2032年全球预测

Dilated Cardiomyopathy Therapeutics Market by Therapeutic Class, Treatment Modality, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，扩大性心肌病治疗市场将成长至 8.3962 亿美元，复合年增长率为 7.90%。

主要市场统计数据
基准年 2024 4.5676亿美元
预计年份：2025年 4.9366亿美元
预测年份：2032年 8.3962亿美元
复合年增长率 (%) 7.90%

本书权威地介绍了扩张型心肌病变治疗的临床复杂性、跨学科护理的演变以及塑造现代扩大性心肌病治疗的创新动态。

扩大性心肌病（DCM）是一种复杂的临床综合征，其特征是心室扩张和收缩功能障碍，导致不同患者群体中出现显着的发病率和死亡率。过去十年，治疗策略已从传统的神经激素阻断扩展到包括先进的器械介入和针对遗传及分子因素的精准医疗。这种发展迫使相关人员重新评估诊疗路径、资源分配和长期管理模式，以反映渐进式改善和突破性创新。

医疗器材创新、精准生技药品和医疗保健服务重新设计的奖励，从根本上重塑了扩大性心肌病的治疗管道和相关人员。

扩大性心肌病的治疗格局正在经历一场变革，这主要得益于技术进步、监管法规的演变以及医疗服务模式的改变。曾经挽救生命的医疗设备，随着越来越多的证据表明其对降低发病率和提高生存率的影响，正被更早地整合到临床诊疗流程中；与此同时，医疗器械的小型化和远程监测能力也在重塑门诊管理和随访的模式。

评估2025年关税变化对全球用于治疗心肌病的医疗器材、生技药品和基因治疗材料的製造、采购和定价策略的影响

2025年生效的新关税将显着增加扩大性心肌病治疗的全球供应链和成本结构的复杂性，尤其是那些国际分销的组件和生技药品。心臟再同步治疗系统、植入式心臟整流去颤器和心室辅助装置等医疗设备都依赖复杂的全球製造网络，包括半导体、感测器和特种合金。上游供应商面临的关税成本压力可能会波及到器械製造商，从而给医院和采购商带来价格压力。

将治疗领域、治疗治疗方法、给药途径、临床环境和分销管道与临床和商业策略联繫起来的综合細項分析

从细分角度分析扩大性心肌病治疗，透过考虑治疗分类、治疗治疗方法、给药途径、终端用户环境和分销管道，可以揭示不同的治疗机会和应用趋势。将治疗层级分为ACE抑制剂、ARB、ARNI、 β阻断剂、器械疗法、利尿剂和基因疗法，可以发现，儘管药物疗法仍然是基础，但器械疗法和基因疗法具有独特的临床和商业性特性。将器械疗法进一步细分为CRT、ICD和VAD，可凸显不同的投资需求和治疗路径需求。依治疗方法类型（器械疗法、基因疗法和药物疗法）进行分析，并认识到药物研发分为生技药品和小分子药物，可以突出研发风险和监管复杂性交彙的领域，以及更适合进行渐进式临床优化的领域。

区域趋势分析：美洲、欧洲、中东、非洲和亚太地区监管、报销和基础设施的差异对治疗方法采纳和取得的影响

区域趋势正在以不同的方式影响扩大性心肌病治疗的研发、应用和交付，美洲、欧洲、中东和非洲以及亚太地区的情况。在美洲，成熟的医疗基础设施和完善的报销体系支持先进医疗设备和新一代生物製药的快速应用，但支付方越来越要求提供严格的卫生经济学证据来证明高成本治疗性介入的合理性。临床网路和专科卓越中心推动了复杂手术和实验室检测的参与，而私人和公共支付方正在就医疗保险条款进行谈判，这将影响商业化策略。

企业策略与竞争策略：医疗设备领导者、生技药品开发商和基因治疗先驱如何整合自身能力以获得长期优势

扩大性心肌病治疗领域的格局呈现出大规模多元化医疗设备製造商、专业生技药品开发商和新兴基因治疗创新者之间策略融合的趋势。成熟的循环系统医疗设备公司持续投资于下一代植入式系统、远端监测环境和手术全期服务模式，以改善患者的长期预后并创造持续的业务收益。这些现有企业正积极寻求补充性收购、合作开发伙伴关係和广泛的临床项目，以保持其在器械领域的领先地位，并拓展至增值相关服务领域。

领导者在推动跨治疗方法和临床环境的证据产生、供应链韧性和整合商业化方面所面临的实际策略挑战

为了在扩大性心肌病治疗领域创造临床和商业性价值，产业领导者应采取多管齐下的策略，优先考虑实证医学证据的累积、供应链的韧性以及整合式商业化。首先，透过务实的测试、真实世界证据计画和註册登记来加强证据基础至关重要，这有助于说服临床医生和支付方认可其带来的增量效益，尤其对于高成本的医疗设备和基因疗法而言。建构一个能够进行长期疗效追踪的互通性资料平台，将有助于进行价值评估并履行上市后承诺。

这份高阶主管分析报告采用透明的调查方法，结合文献回顾、相关人员访谈、临床註册分析和情境评估，得出可靠的策略结论。

本执行分析所依据的研究结合了对同侪审查文献、监管申报文件和临床试验註册库的系统性回顾，以及针对整个生态系统的重点基础研究。文献综述纳入了最新的指南共识声明和具有影响力的临床研究，以确保与目前的医疗标准保持一致。透过审查临床试验註册库和公开的监管申报文件，我们整理了医疗设备和基因治疗候选药物的临床实验项目和预期里程碑。

权威的综合分析重点阐述了临床创新、证据深度和操作适应性在扩大性心肌病治疗中如何决定未来治疗方案的采纳和可及性。

扩大性心肌病治疗正处于转折点，医疗设备创新、生技药品和基因组医学的融合拓展了治疗的可能性，同时也增加了研发、交付和报销管道的复杂性。能够将临床严谨性与营运灵活性相结合的相关人员，将更有能力将科学进步转化为有意义的患者疗效和可持续的商业模式。不断变化的医疗保健格局要求重新调整投资重点，并专注于循证医学、区域供应链策略和价值驱动的商业化。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 针对扩大性心肌病肌节蛋白突变的基因治疗取得进展
  • 穿戴式心臟监测设备在扩大性心肌病病变患者早期检测心室功能障碍的临床应用
  • 引入新型肌凝蛋白调节剂以改善扩大性心肌病治疗的左心室射血分数
  • 开发RNA干扰疗法以抑制扩大性心肌病中通道的适应不良性重塑
  • 扩大多学科心臟衰竭诊疗范围，纳入遗传咨询和个人化医疗方法
  • 利用心臟磁振造影应变变成像生物标记指导扩大性心肌病患者的治疗决策
  • 肠道菌丛调节在抑制扩大性心肌病发炎进展的新兴作用
  • 监管加速推进用于扩大性心肌病心肌再生的新型细胞疗法

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗类别扩大性心肌病治疗市场

  • ACE抑制剂
  • ARB
  • ARNI
  • β阻断剂
  • 器械疗法
    • CRT
    • ICD
    • 辅助人工心臟（VAD）
  • 利尿剂
  • 基因治疗

第九章扩大性心肌病治疗市场（依治疗方法）

  • 基于设备的
  • 基因治疗
  • 药物治疗
    • 生技药品
    • 低分子化合物

第十章 依给药途径扩大性心肌病治疗市场

  • 静脉注射
  • 口服

第十一章扩大性心肌病治疗市场（依最终用户划分）

  • 居家医疗
  • 医院
  • 专科诊所

第十二章扩大性心肌病治疗市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十三章扩大性心肌病治疗市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章扩大性心肌病治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国扩大性心肌病治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Boehringer Ingelheim International GmbH
    • Novartis International AG
    • AstraZeneca PLC
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Medtronic plc
    • Boston Scientific Corporation
    • Abbott Laboratories
    • Amgen Inc.
    • Laboratoires Servier SAS
Product Code: MRR-8E22B61932B4

The Dilated Cardiomyopathy Therapeutics Market is projected to grow by USD 839.62 million at a CAGR of 7.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 456.76 million
Estimated Year [2025] USD 493.66 million
Forecast Year [2032] USD 839.62 million
CAGR (%) 7.90%

An authoritative introduction framing the clinical complexity, multidisciplinary care evolution, and innovation dynamics shaping modern dilated cardiomyopathy therapeutics

Dilated cardiomyopathy (DCM) represents a complex clinical syndrome characterized by ventricular dilation and systolic dysfunction that leads to substantial morbidity and mortality across diverse patient populations. Over the past decade, therapeutic strategies have expanded beyond traditional neurohormonal blockade to include advanced device interventions and precision medicines that target genetic and molecular drivers. This evolution compels stakeholders to reassess care pathways, resource allocation, and long-term management models to reflect both incremental improvements and step-change innovations.

Clinical practice is adapting to a more heterogeneous patient profile, where early identification of genetic etiologies and nuanced phenotyping inform personalized treatment plans. As a result, multidisciplinary teams spanning cardiology, electrophysiology, genetics, and allied health professionals are increasingly central to therapy selection and ongoing monitoring. Payers and health systems are likewise recalibrating coverage frameworks to address up-front costs associated with devices and gene-based interventions while evaluating downstream reductions in hospitalizations and complications.

From an innovation perspective, the interplay between device engineering, biologic therapeutics, and small-molecule optimization has created a richer set of options for clinicians and patients. Consequently, strategic planning in this therapeutic area requires a granular understanding of segment dynamics, regulatory trajectories, clinical trial readouts, and real-world evidence as they converge to influence adoption, care delivery, and investment priorities.

How converging device innovation, precision biologics, and care delivery redesign are fundamentally reshaping therapeutic pathways and stakeholder incentives in dilated cardiomyopathy

The therapeutic landscape for dilated cardiomyopathy is undergoing transformative shifts driven by converging technological advances, regulatory evolution, and changing care delivery models. Devices that once served as rescue interventions are now being integrated earlier in clinical pathways as evidence accumulates about their impact on morbidity and survival, while miniaturization and remote-monitoring capabilities are reshaping outpatient management and follow-up intensity.

Simultaneously, precision medicine is moving from promise to practice. Gene therapies and targeted biologics are advancing through clinical development with increasingly sophisticated patient selection strategies that leverage genetic testing and biomarker profiling. This is accompanied by a rethinking of clinical trial designs toward adaptive models and real-world endpoints that better reflect heterogeneous patient populations. The pharmacological landscape remains important, with refined small molecules and novel biologic constructs aimed at neurohormonal modulation and myocardial remodeling complementing device-based modalities.

Distribution and care settings are being reimagined; hospitals remain centers of acute care and implantation, but a shift toward homecare, remote titration, and specialty clinics for longitudinal management is evident. These delivery changes are enabled by digital health platforms, interoperability between monitoring devices and electronic records, and greater emphasis on patient-reported outcomes. Collectively, these shifts are not incremental but structural, altering how products are developed, positioned, and reimbursed, and placing a premium on integrated strategies that bridge devices, biologics, and services.

Assessment of how 2025 tariff shifts are reshaping global manufacturing, procurement, and pricing strategies across devices, biologics, and gene therapy inputs in cardiomyopathy care

The introduction of new tariff measures in 2025 adds a significant layer of complexity to global supply chains and cost structures in dilated cardiomyopathy therapeutics, particularly for components and biologic inputs that cross international borders. Medical devices such as cardiac resynchronization therapy systems, implantable cardioverter-defibrillators, and ventricular assist devices depend on intricate global manufacturing networks for semiconductors, sensors, and specialized alloys. Tariff-induced cost pressures on upstream suppliers can cascade to device manufacturers, creating potential pricing tensions for hospitals and purchasers.

On the pharmacological and gene therapy side, manufacturing inputs for vectors, viral production, and complex biologic reagents often involve cross-border sourcing of raw materials and specialized processing equipment. Increased import duties or customs friction can lengthen lead times and raise production costs, prompting sponsors to re-evaluate contract manufacturing strategies, regionalize production, or accelerate technology transfers. These operational responses can mitigate exposure but require capital investment and regulatory coordination that take time to realize.

For health systems and payers, the net effect of tariff-driven cost changes may be felt through procurement cycles and capital budgeting for device programs, as well as through negotiated pricing for high-cost biologics and gene-based therapeutics. In response, manufacturers may pursue differentiated pricing models, local manufacturing partnerships, or outcomes-based contracting to preserve access while maintaining commercial viability. Finally, regulatory and reimbursement stakeholders are likely to scrutinize value propositions more closely, linking coverage decisions to robust clinical and economic evidence as part of a broader adaptation to changing input costs.

Integrated segmentation insights that connect therapeutic classes, treatment modalities, administration routes, care settings, and distribution channels to clinical and commercial strategy

A segmentation-aware view of dilated cardiomyopathy therapeutics reveals differentiated opportunities and adoption dynamics when consideration is given to therapeutic class, treatment modality, administration route, end-user environment, and distribution pathway. When therapeutic class is parsed into ACE inhibitor, Arb, Arni, Beta Blocker, Device Therapy, Diuretic, and Gene Therapy, it becomes clear that medical management remains foundational while device therapy and gene therapy introduce distinct clinical and commercial characteristics; further granularity in device therapy across Crt, Icds, and Vad highlights heterogeneous investment and care pathway requirements. Looking through the lens of treatment modality-Device Based, Gene Therapy, and Pharmacological-and recognizing that pharmacological development bifurcates into Biologics and Small Molecule approaches-clarifies where development risk and regulatory complexity converge versus where incremental clinical optimization is more feasible.

Route of administration further stratifies operational considerations: Intravenous modalities carry implications for inpatient or clinic-based delivery infrastructures, whereas Oral therapies enable broader outpatient management and adherence-focused interventions. End user segmentation across Homecare, Hospital, and Specialty Clinic settings emphasizes shifting touchpoints for follow-up, titration, and device monitoring, with homecare growth accelerating needs for remote monitoring and caregiver support. Finally, distribution channel differentiation among Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies shapes logistics, inventory strategies, and patient access patterns, influencing how manufacturers and payers design distribution agreements and patient support programs.

Integrating these segmentation dimensions enables a clearer mapping of clinical value to commercial levers. For example, gene therapy candidates may require specialized distribution and hospital-based administration while oral small molecules can be deployed broadly through retail pharmacies. Devices necessitate capital procurement and post-implant surveillance, elevating the importance of durable service agreements and interoperability with clinical IT systems. Understanding these intersections is critical for prioritizing R&D investments, tailoring market access plans, and designing patient-centered support models.

Regional dynamics analysis describing how heterogeneous regulatory, reimbursement, and infrastructure factors in the Americas, EMEA, and Asia-Pacific influence therapy adoption and access

Regional dynamics are shaping the development, adoption, and delivery of dilated cardiomyopathy therapeutics in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, mature care infrastructures and well-established reimbursement frameworks support rapid adoption of advanced devices and next-generation biologics, though payers increasingly demand rigorous health-economic evidence to justify high-cost interventions. Clinical networks and specialized centers of excellence facilitate complex procedures and clinical trial enrollment, while private and public payers negotiate coverage conditions that influence commercialization strategies.

Across Europe, Middle East & Africa, the region exhibits considerable heterogeneity driven by national regulatory, reimbursement, and health system structures. Western European markets often mirror North American pathways with structured adoption of devices and biologics, whereas emerging markets within the region face capacity constraints that may delay deployment of complex therapies. Policy emphasis on cost-effectiveness and centralized HTA processes shapes pricing strategies and can incentivize local evidence generation or managed entry agreements.

In the Asia-Pacific region, rapid investments in hospital infrastructure and a growing emphasis on cardiovascular disease management are expanding patient access to advanced therapies. Regulatory pathways in several jurisdictions have been modernized to facilitate expedited review for innovative therapeutics, and local manufacturing initiatives are increasingly pursued to reduce import dependency. Regional collaboration and harmonization efforts are creating new avenues for clinical research and could accelerate broader adoption of device-based and gene-focused interventions when combined with strategic partnerships and localized market access approaches.

Corporate positioning and competitive maneuvers revealing how device leaders, biologics developers, and gene therapy pioneers are aligning capabilities for long-term advantage

The corporate landscape in dilated cardiomyopathy therapeutics is marked by strategic convergence between large diversified device manufacturers, specialist biologics developers, and emerging gene therapy innovators. Established cardiovascular device firms continue to invest in next-generation implantable systems, remote monitoring ecosystems, and peri-procedural service models that enhance long-term patient outcomes and create recurring service revenues. These incumbents often pursue bolt-on acquisitions, co-development partnerships, and broad-based clinical programs to sustain device leadership while expanding into adjacent value-added services.

Biopharmaceutical companies with cardiovascular portfolios are diversifying through targeted biologics and small-molecule programs that address myocardial remodeling and neurohormonal pathways. Simultaneously, biotechnology firms focused on gene editing and vectorized gene replacement are advancing candidates that target defined genetic etiologies of dilated cardiomyopathy, fostering collaborations with manufacturing specialists and clinical research networks to manage development complexity and scale-up risks. Cross-sector alliances between device makers and biologic developers are becoming more common, particularly where combination therapies or diagnostic-enabled patient selection can enhance therapeutic impact.

Competitive differentiation increasingly hinges on evidentiary depth, post-market surveillance capabilities, and the ability to demonstrate real-world value. Companies that invest in longitudinal data platforms, patient support programs, and integrated care solutions are better positioned to engage payers and care providers. Moreover, strategic moves such as regional manufacturing investments, outcomes-based contracting pilots, and early engagement with regulatory agencies are shaping which players can effectively translate scientific advances into sustainable commercial success.

Actionable strategic imperatives for leaders to fortify evidence generation, supply resilience, and integrated commercialization across therapeutics and care settings

Industry leaders should pursue a multi-dimensional strategy that prioritizes evidence generation, supply chain resilience, and integrated commercialization to capture clinical and commercial value in dilated cardiomyopathy therapeutics. First, strengthening the evidence base through pragmatic trials, real-world evidence programs, and registries will be essential to convince clinicians and payers of incremental benefits, particularly for high-cost devices and gene-based therapies. Building interoperable data platforms that facilitate long-term outcome tracking will support value-based conversations and post-market commitments.

Second, diversifying manufacturing footprints and establishing qualified regional partners can mitigate tariff and logistics risks while reducing lead times for critical inputs. Investing in technology transfer and quality systems in strategically selected regions will enable faster response to demand shifts and regulatory requirements. Third, commercial strategies must be aligned to care settings: tailored access programs for hospital procurement, streamlined pathways for specialty clinics, and patient adherence solutions for oral therapies will improve uptake across end-user segments.

Finally, forging cross-sector partnerships-linking device capabilities with pharmacological innovations and digital health tools-can create differentiated offerings that address both clinical and operational pain points. Leaders should also engage early with regulators and HTA bodies to co-design evidence packages and explore innovative reimbursement arrangements. Executed together, these actions will help organizations navigate evolving policy environments, demonstrate sustainable value, and enhance patient access to advanced therapies.

Transparent methodology integrating literature synthesis, stakeholder interviews, clinical registry analysis, and scenario evaluations to support robust strategic conclusions

The research underpinning this executive analysis combined a structured review of peer-reviewed literature, regulatory filings, and clinical trial registries with targeted primary engagements across the ecosystem. Literature synthesis included recent guidelines, consensus statements, and high-impact clinical studies to ensure alignment with current standards of care. Clinical trial registries and public regulatory filings were examined to map investigational programs and expected milestones for device and gene therapy candidates.

Primary research consisted of interviews with cardiologists, electrophysiologists, health system procurement leads, clinical researchers, and patient advocacy representatives to capture front-line perspectives on adoption barriers and clinical unmet needs. These qualitative insights were triangulated with secondary sources, including manufacturing and supply chain publications, technology briefs, and policy analyses, to assemble a holistic view of operational and regulatory dynamics. Data quality protocols involved cross-validation of key assertions against multiple independent sources and sensitivity checks to identify areas of higher uncertainty.

Analytical approaches included segmentation mapping across therapeutic class, modality, administration route, end user, and distribution channel, as well as scenario-based assessment of tariff and supply chain impacts. The methodology emphasized transparency in assumptions and explicit documentation of evidence sources to facilitate verification and to support subsequent deep-dive investigations.

A conclusive synthesis highlighting how clinical innovation, evidence depth, and operational adaptability will determine future adoption and access in dilated cardiomyopathy care

Dilated cardiomyopathy therapeutics are at an inflection point where device innovation, biologic advancement, and genomic medicine are converging to expand treatment possibilities while simultaneously increasing complexity across development, delivery, and reimbursement pathways. Stakeholders who can integrate clinical rigor with operational agility will be best positioned to translate scientific progress into meaningful patient outcomes and sustainable commercial models. The evolving care landscape requires a recalibration of investment priorities, with emphasis on evidence generation, regional supply chain strategies, and value-aligned commercialization.

Adoption trajectories will be shaped not only by clinical efficacy but also by the ability to demonstrate real-world benefit, manage total cost of care, and adapt to shifting policy environments such as tariff-induced supply changes and evolving HTA expectations. Cross-disciplinary collaboration among clinicians, manufacturers, payers, and regulators will be essential to navigate these dynamics and to create durable pathways for patient access. Ultimately, the organizations that combine scientific excellence with pragmatic delivery models and strong stakeholder engagement will set the cadence for the next era of dilated cardiomyopathy care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in gene therapy targeting sarcomeric protein mutations in dilated cardiomyopathy
  • 5.2. Clinical integration of wearable cardiac monitoring devices for early detection of ventricular dysfunction in DCM patients
  • 5.3. Adoption of novel myosin modulators to improve left ventricular ejection fraction in DCM management
  • 5.4. Development of RNA interference therapies to silence maladaptive remodeling pathways in dilated cardiomyopathy
  • 5.5. Expansion of multidisciplinary heart failure clinics incorporating genetic counseling and personalized medicine approaches
  • 5.6. Use of cardiac MRI strain imaging biomarkers to guide therapeutic decisions for dilated cardiomyopathy patients
  • 5.7. Emerging role of gut microbiome modulation in attenuating inflammatory progression in dilated cardiomyopathy
  • 5.8. Regulatory acceleration of novel cell-based therapies for myocardial regeneration in dilated cardiomyopathy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dilated Cardiomyopathy Therapeutics Market, by Therapeutic Class

  • 8.1. Ace Inhibitor
  • 8.2. Arb
  • 8.3. Arni
  • 8.4. Beta Blocker
  • 8.5. Device Therapy
    • 8.5.1. Crt
    • 8.5.2. Icds
    • 8.5.3. Vad
  • 8.6. Diuretic
  • 8.7. Gene Therapy

9. Dilated Cardiomyopathy Therapeutics Market, by Treatment Modality

  • 9.1. Device Based
  • 9.2. Gene Therapy
  • 9.3. Pharmacological
    • 9.3.1. Biologics
    • 9.3.2. Small Molecule

10. Dilated Cardiomyopathy Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Dilated Cardiomyopathy Therapeutics Market, by End User

  • 11.1. Homecare
  • 11.2. Hospital
  • 11.3. Specialty Clinic

12. Dilated Cardiomyopathy Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Dilated Cardiomyopathy Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dilated Cardiomyopathy Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dilated Cardiomyopathy Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Boehringer Ingelheim International GmbH
    • 16.3.2. Novartis International AG
    • 16.3.3. AstraZeneca PLC
    • 16.3.4. Johnson & Johnson
    • 16.3.5. Merck & Co., Inc.
    • 16.3.6. Medtronic plc
    • 16.3.7. Boston Scientific Corporation
    • 16.3.8. Abbott Laboratories
    • 16.3.9. Amgen Inc.
    • 16.3.10. Laboratoires Servier SAS

LIST OF FIGURES

  • FIGURE 1. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ACE INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ARNI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA BLOCKER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CRT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ICDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY VAD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DIURETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-